Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Integrating precision oncology into MDT decision-making

Elzbieta Senkus-Konefka • 14 Mar 2025
BCC 2025
Breast Cancer

Elżbieta Senkus-Konefka, MD, PhD, Medical University of Gdańsk, Gdańsk, Poland, explores the integration of clinical and biological factors in multi-disciplinary team (MDT) decision-making. This emphasizes selecting validated tools, optimising treatment choice based on tumour characteristics, and ensuring resources are used effectively to benefit the right patients. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Elzbieta Senkus-Konefka

Circumstantial treatment de-escalation in early breast cancer
2:02
Circumstantial treatment de-escalation in early breast cancer
Elzbieta Senkus-Konefka • 14 Mar 2025
Multidisciplinary decision-making in breast cancer
1:57
Multidisciplinary decision-making in breast cancer
Elzbieta Senkus-Konefka • 14 Mar 2025
What have we learned from recent clinical trials in early breast cancer treatment?
4:13
What have we learned from recent clinical trials in early breast cancer treatment?
Elzbieta Senkus-Konefka • 21 Sep 2017
The importance of the OlympiA trial for breast cancer patients
2:18
The importance of the OlympiA trial for breast cancer patients
Elzbieta Senkus-Konefka • 21 Sep 2017

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals